Swiss National Bank Sells 12,500 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Swiss National Bank trimmed its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 5.1% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 232,600 shares of the company's stock after selling 12,500 shares during the period. Swiss National Bank owned about 0.28% of IDEXX Laboratories worth $96,166,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of the company. FSA Wealth Management LLC bought a new stake in shares of IDEXX Laboratories in the 3rd quarter worth approximately $25,000. Rialto Wealth Management LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth $30,000. Retirement Wealth Solutions LLC purchased a new stake in IDEXX Laboratories during the fourth quarter valued at about $31,000. Kestra Investment Management LLC bought a new position in shares of IDEXX Laboratories during the fourth quarter valued at about $38,000. Finally, Crews Bank & Trust purchased a new position in shares of IDEXX Laboratories in the fourth quarter worth about $41,000. Institutional investors own 87.84% of the company's stock.

Analyst Upgrades and Downgrades

Several analysts have weighed in on IDXX shares. Bank of America boosted their price objective on IDEXX Laboratories from $475.00 to $535.00 and gave the company a "neutral" rating in a research report on Tuesday, February 4th. Piper Sandler increased their price target on shares of IDEXX Laboratories from $435.00 to $510.00 and gave the company a "neutral" rating in a research report on Monday, February 10th. StockNews.com cut shares of IDEXX Laboratories from a "buy" rating to a "hold" rating in a research report on Saturday. Morgan Stanley dropped their target price on shares of IDEXX Laboratories from $559.00 to $550.00 and set an "overweight" rating for the company in a report on Wednesday, January 29th. Finally, Leerink Partners started coverage on IDEXX Laboratories in a report on Monday, December 2nd. They set an "outperform" rating and a $500.00 price target on the stock. Four research analysts have rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has a consensus rating of "Moderate Buy" and a consensus price target of $533.75.

Remove Ads

IDEXX Laboratories Stock Up 0.6 %

IDXX traded up $2.63 during trading on Wednesday, hitting $422.15. 463,314 shares of the company's stock traded hands, compared to its average volume of 548,742. The stock has a market capitalization of $34.33 billion, a price-to-earnings ratio of 39.56, a PEG ratio of 3.41 and a beta of 1.39. The company's 50 day simple moving average is $437.74 and its two-hundred day simple moving average is $445.87. IDEXX Laboratories, Inc. has a 12-month low of $398.50 and a 12-month high of $548.88. The company has a current ratio of 1.31, a quick ratio of 0.95 and a debt-to-equity ratio of 0.28.

Insider Activity

In other IDEXX Laboratories news, Director M Anne Szostak sold 3,000 shares of the company's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $465.94, for a total transaction of $1,397,820.00. Following the transaction, the director now owns 3,061 shares in the company, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP George Fennell sold 9,986 shares of the firm's stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $462.53, for a total transaction of $4,618,824.58. Following the sale, the executive vice president now directly owns 8,176 shares in the company, valued at approximately $3,781,645.28. The trade was a 54.98 % decrease in their position. The disclosure for this sale can be found here. Corporate insiders own 2.11% of the company's stock.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.